Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 2
2007 1
2013 1
2014 1
2016 1
2018 2
2019 2
2022 2
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Among authors: christensen jh. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, Morschhauser F, Alpdogan O, Suh C, Tobinai K, Shustov A, Trneny M, Yuen S, Zinzani PL, Trümper L, Ilidge T, O'Connor OA, Pro B, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Iyer S. Savage KJ, et al. Among authors: christensen jh. Blood Adv. 2022 Oct 11;6(19):5550-5555. doi: 10.1182/bloodadvances.2020003971. Blood Adv. 2022. PMID: 35470385 Free PMC article. Clinical Trial.
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.
Jerkeman M, Kolstad A, Hutchings M, Pasanen A, Meriranta L, Niemann CU, Kragh Jørgensen RR, El-Galaly TC, Riise J, Leppä S, Christensen JH, Sonnevi K, Pedersen LB, Wader KF, Glimelius I. Jerkeman M, et al. Among authors: christensen jh. Blood Adv. 2024 Jan 23;8(2):407-415. doi: 10.1182/bloodadvances.2023011920. Blood Adv. 2024. PMID: 38113470 Free PMC article. Clinical Trial.
Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry.
Andersen MD, Hamilton-Dutoit S, Modvig L, Vase M, Christiansen I, Christensen JH, Dahl-Sørensen RB, Stoltenberg D, Kamper P, d'Amore F. Andersen MD, et al. Among authors: christensen jh. Br J Haematol. 2022 Jul;198(1):50-61. doi: 10.1111/bjh.18180. Epub 2022 Apr 8. Br J Haematol. 2022. PMID: 35396711 Free PMC article. Review.
Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas.
Biccler JL, El-Galaly TC, Bøgsted M, Jørgensen J, de Nully Brown P, Poulsen CB, Starklint J, Juul MB, Christensen JH, Josefsson P, Dessau A, Jakobsen LH. Biccler JL, et al. Among authors: christensen jh. Leuk Lymphoma. 2019 Jun;60(6):1580-1583. doi: 10.1080/10428194.2018.1540044. Epub 2018 Nov 14. Leuk Lymphoma. 2019. PMID: 30424711 No abstract available.
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.
Zinzani PL, Trněný M, Ribrag V, Zilioli VR, Walewski J, Christensen JH, Delwail V, Rodriguez G, Venugopal P, Coleman M, Dartigeas C, Patti C, Pane F, Jurczak W, Taszner M, Paneesha S, Zheng F, DeMarini DJ, Jiang W, Gilmartin A, Mehta A. Zinzani PL, et al. Among authors: christensen jh. EClinicalMedicine. 2023 Aug 10;62:102131. doi: 10.1016/j.eclinm.2023.102131. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37599908 Free PMC article.
The Danish National Lymphoma Registry: Coverage and Data Quality.
Arboe B, El-Galaly TC, Clausen MR, Munksgaard PS, Stoltenberg D, Nygaard MK, Klausen TW, Christensen JH, Gørløv JS, Brown Pde N. Arboe B, et al. Among authors: christensen jh. PLoS One. 2016 Jun 23;11(6):e0157999. doi: 10.1371/journal.pone.0157999. eCollection 2016. PLoS One. 2016. PMID: 27336800 Free PMC article.
Machine Learning-Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma.
Rask Kragh Jørgensen R, Bergström F, Eloranta S, Tang Severinsen M, Bjøro Smeland K, Fosså A, Haaber Christensen J, Hutchings M, Bo Dahl-Sørensen R, Kamper P, Glimelius I, E Smedby K, K Parsons S, Mae Rodday A, J Maurer M, M Evens A, C El-Galaly T, Hjort Jakobsen L. Rask Kragh Jørgensen R, et al. Among authors: haaber christensen j. JCO Clin Cancer Inform. 2024 Apr;8:e2300255. doi: 10.1200/CCI.23.00255. JCO Clin Cancer Inform. 2024. PMID: 38608215 Free PMC article.
Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study.
Vandtved JH, Øvlisen AK, Baech J, Weinrich UM, Severinsen MT, Maksten EF, Jakobsen LH, Glimelius I, Kamper P, Hutchings M, Specht L, Dahl-Sørensen R, Christensen JH, El-Galaly TC. Vandtved JH, et al. Among authors: christensen jh. Br J Haematol. 2024 Apr 29. doi: 10.1111/bjh.19475. Online ahead of print. Br J Haematol. 2024. PMID: 38685596
14 results